You are here

Novartis

Amid tough competition, Novartis makes case for rheumatology drug Cosentyx

Pharmaforum

Thu, 06/14/18 - 10:35 pm

ankylosing spondylitis

Is the future of therapy online? Swiss drug giant Novartis thinks so

Marketwatch

Wed, 06/13/18 - 09:39 am

Pear Therapeutics

digital therapeutics

Swiss Won’t Investigate Novartis Over Payments to Cohen

Bloomberg

Thu, 06/7/18 - 11:30 am

Migraine Breakthrough: Not So Fast

Forbes

Wed, 06/6/18 - 09:49 pm

monoclonal antibodies

ASCO: Novartis makes a case for earlier Kisqali use. Will 'conservative' docs run with it?

Fierce Pharma

Mon, 06/4/18 - 09:31 am

metastatic breast cancer

HER2-negative breast cancer

NTC acquires part of Novartis’ ophthalmic portfolio

GoinPharma

Sat, 06/2/18 - 01:46 pm

How Novartis, Insurers Are Taking Wind Out Of AbbVie's Sales

Investors Business Daily

Fri, 06/1/18 - 10:43 pm

Novartis receives EU approval for biosimilar Zessly

Reuters

Thu, 05/24/18 - 09:38 pm

Novartis' brand-new gene therapy player AveXis will build $55M plant, hire 200

Fierce Pharma

Wed, 05/23/18 - 03:03 pm

drug manufacturing

Cohen scandal disrupts ex-Novartis CEO's move to hedge fund board: WSJ

Fierce Pharma

Tue, 05/22/18 - 06:09 pm

Breast Cancer Cells Use In-House Recycling To Survive After Spreading

Forbes

Tue, 05/22/18 - 06:03 pm

metastatic breast cancer

Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst

CNBC

Sat, 05/19/18 - 11:30 am

Amgen’s new migraine drug will cost 30 percent less than Wall Street expected

Stat

Thu, 05/17/18 - 09:48 pm

Amgen's Aimovig won its first-in-class migraine nod. Will payers step up to the $6,900 price?

Fierce Pharma

Thu, 05/17/18 - 09:42 pm

FDA calls out 39 drug companies for allegedly blocking access to generics

Stat

Thu, 05/17/18 - 10:15 am

Valeant Pharmaceuticals

Former Novartis CEO Explains Why His Company Paid Trump Lawyer Michael Cohen $1.2 Million

Forbes

Wed, 05/16/18 - 11:04 am

Novartis chief lawyer departing over company’s payments made to Cohen

Stat

Wed, 05/16/18 - 09:00 am

Novartis CEO Vas Narasimhan faces a heap of burning questions — but so far offers no public answers

Endpoints

Tue, 05/15/18 - 09:11 pm

Swiss prosecutor eyes Novartis deal with Cohen, but no criminal probe is underway — for now

Stat

Mon, 05/14/18 - 11:05 pm

List of likely buyers of Novartis’ Dermatology division ($2bn) takes shape

GoinPharma

Mon, 05/14/18 - 09:32 am

Shanghai Fosun Pharmaceutical

Apollo Global Management

Pages